A personalized treatment for lung cancer: Molecular pathways, targeted therapies, and genomic characterization

Advances in Experimental Medicine and Biology

Volumn 799, Issue , 2014, Pages 85-117

  Hensing, Thomas ^a,b   Chawla, Apoorva ^b   Batra, Rishi ^c   Salgia, Ravi ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; PEMETREXED; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REACTIVE OXYGEN SPECIES 1; SCATTER FACTOR RECEPTOR; SELUMETINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; GENE MUTATION; GENE TRANSLOCATION; GENOME ANALYSIS; GENOMICS; GENOTYPE; HISTOLOGY; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENCE ANALYSIS;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM PROTEINS; SMALL CELL LUNG CARCINOMA;

EID: 84934436008     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8778-4_5     Document Type: Article

References (133)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29
2. Malvezzi M, Bertuccio P, Levi F et al (2013) European cancer mortality predictions for the year 2013. Ann Oncol 24(3):792-800
3. American Cancer Society (2012) Cancer facts & fi gures. Atlanta, American Cancer Society
4. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review (1975-2007) National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/ 975-2007/based on Nov 2009 SEER data submission, posted to the SEER website, 2010. Accessed 24 Feb 2013
5. Health Service, Centers for Disease Control and Prevention, Washington, DC, 2010. Smoking and tobacco use - fact sheets. http://www.cdc.gov/tobacco/ data-statistics/fact-sheets/. Accessed 24 Feb 2013
6. Schroeder SA (2013) New evidence that cigarette smoking remains the most important health hazard. N Engl J Med 368(4):389-390
7. Alberg AJ, Nonemaker J (2008) Who is at high risk for lung cancer Population-level and individual-level perspectives. Semin Respir Crit Care Med 29(3):223-232
8. Godtfredsen NS, Prescott E, Osler M (2005) Effect of smoking reduction on lung cancer risk. JAMA 294(12):1505-1510
9. Bruske-Hohlfeld I (2009) Environmental and occupational risk factors for lung cancer. Methods Mol Biol 472:3-23
10. Sim MR (2013) A worldwide ban on asbestos production and use: Some recent progress, but more still to be done. Occup Environ Med 70(1):1-2
11. Matakidou A, Eisen T, Houlston RS (2005) Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 93(7):825-833
12. Ihsan R, Chauhan PS, Mishra AK et al (2011) Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 6(12):e29431
13. Tockman MS (1986) Survival and mortality from lung cancer in a screened population. Chest 89(4 suppl):324S-325S
14. Tockman MS, Mulshine JL (1997) Sputum screening by quantitative microscopy: A new dawn for detection of lung cancer Mayo Clin Proc 72(8):788-790
15. Prorok PC, Andriole GL, Bresalier RS et al (2000) Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 Suppl):273S-309S
16. Bach PB, Mirkin JN, Oliver TK et al (2012) Benefi ts and harms of CT screening for lung cancer: A systematic review. JAMA 307(22):2418-2429
17. Aberle DR, Adams AM, Berg CD, et al, for the National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395-409
18. Dancey JE, Dobbin KK, Groshen S et al (2010) Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16(6):1745-1755
19. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184-2191
20. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550
21. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 26(21):3543-3551
22. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374(9699):1432-1440
23. Giovannetti E, Mey V, Nannizzi S et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110-118
24. Maziak DE, Darling GE, Inculet RI et al (2009) Positron emission tomography in staging early lung cancer: A randomized trial. Ann Intern Med 151(4):221-228, W-48
25. Luke WP, Pearson FG, Todd TR et al (1986) Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg 91(1):53-56
26. Vilmann P, Krasnik M, Larsen SS et al (2005) Transesophageal endoscopic ultrasoundguided fi ne-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: A combined approach in the evaluation of mediastinal lesions. Endoscopy 37(9):833-839
27. Goldstraw P (2009) The 7th edition of TNM in lung cancer: what now J Thorac Oncol 4(6):671-673
28. Groome PA, Bolejack V, Crowley JJ et al (2007) The IASLC Lung Cancer Staging Project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classifi cation of malignant tumours. J Thorac Oncol 2(8):694-705
29. Doddoli C, D'Journo B, Le Pimpec-Barthes F et al (2005) Lung cancer invading the chest wall: A plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg 80(6):2032-2040
30. Yan TD, Black D, Bannon PG et al (2009) Systematic review and meta-analysis of randomized and nonrandomized trials on safety and effi cacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol 27(15):2553-2562
31. Petersen RP, Pham D, Burfeind WR et al (2007) Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg 83(4):1245-1249, discussion 50
32. Ferguson MK, Lehman AG (2003) Sleeve lobectomy or pneumonectomy: Optimal management strategy using decision analysis techniques. Ann Thorac Surg 76(6):1782-1788
33. Strauss GM, Herndon JE 2nd, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26(31):5043-5051
34. Heon S, Johnson BE (2012) Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 144(3):S39-S42
35. Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7(9):719-727
36. Pisters KM, Evans WK, Azzoli CG et al (2007) Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25(34):5506-5518
37. Douillard JY, Rosell R, De Lena M et al (2008) Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 72(3):695-701
38. Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452-1460
39. Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18(3):349-351
40. Kris MG, Johnson BE, Kwiatkowski DJ et al (2011) Identifi cation of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29:477s, suppl 15; abstr CRA 7506
41. Vignot S, Frampton GM, Soria JC et al (2013). Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. Epub ahead of print.
42. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-1380
43. Herbst RS, Maddox AM, Rothenberg ML et al (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in nonsmall- cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20(18):3815-3825
44. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefi tinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12):2237-2246
45. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib. N Engl J Med 350(21):2129-2139
46. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefi tinib therapy. Science 304(5676):1497-1500
47. Marks JL, Broderick S, Zhou Q et al (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3(2):111-116
48. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant nonsmall- cell lung cancer. Nat Rev Cancer 10(11):760-774
49. Mok TS, Wu YL, Thongprasert S et al (2009) Gefi tinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
50. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefi tinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388
51. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefi tinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128
52. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
53. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26
54. Soh J, Okumura N, Lockwood WW et al (2009) Oncogene mutations, copy number gains and mutant allele specifi c imbalance (MASI) frequently occur together in tumor cells. PLoS One 4(10):e7464
55. Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075
56. Yun CH, Boggon TJ, Li Y et al (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227
57. Carey KD, Garton AJ, Romero MS et al (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66(16):8163-8171
58. Gong Y, Somwar R, Politi K et al (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4(10):e294
59. Deng J, Shimamura T, Perera S et al (2007) Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67(24):11867-11875
60. Greulich H, Chen TH, Feng W et al (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2(11):e313
61. Prudkin L, Tang X, Wistuba II (2009) Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 4(1):139-141
62. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefi tinib or erlotinib. PLoS Med 2(1):e17
63. Roberts PJ, Stinchcombe TE (2013) KRAS mutation: Should we test for it, and does it matter J Clin Oncol 31(8):1112-1121
64. Sos ML, Koker M, Weir BA et al (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69(8):3256-3261
65. Yano S, Wang W, Li Q et al (2008) Hepatocyte growth factor induces gefi tinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22):9479-9487
66. Jackman D, Pao W, Riely GJ et al (2010) Clinical defi nition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28(2):357-360
67. Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affi nity for ATP. Proc Natl Acad Sci U S A 105(6):2070-2075
68. Oxnard GR, Arcila ME, Sima CS et al (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17(6):1616-1622
69. Bean J, Riely GJ, Balak M et al (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14(22):7519-7525
70. Bean J, Brennan C, Shih JY et al (2007) MET amplifi cation occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefi tinib or erlotinib. Proc Natl Acad Sci U S A 104(52):20932-20937
71. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplifi cation leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043
72. Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505-509
73. Jagadeeswaran R, Surawska H, Krishnaswamy S et al (2008) Paxillin is a target for somatic mutations in lung cancer: Implications for cell growth and invasion. Cancer Res 68(1):132-142
74. Straussman R, Morikawa T, Shee K et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500-504
75. Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702-4711
76. Xu L, Kikuchi E, Xu C et al (2012) Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 72(13):3302-3311
77. Yang JC-H, Schuler MH, Yamamoto N et al LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as fi rst-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. 2012 ASCO annual meeting. Abstract LBA7500. Presented 4 June 2012.
78. Li D, Shimamura T, Ji H et al (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12(1):81-93
79. Chaft JE, Oxnard GR, Sima CS et al (2011) Disease fl are after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefi tinib: Implications for clinical trial design. Clin Cancer Res 17(19):6298-6303
80. Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplifi cation in EGFR mutant NSCLC. Cancer Cell 17(1):77-88
81. Morris SW, Kirstein MN, Valentine MB et al (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267(5196):316-317
82. Soda M, Choi YL, Enomoto M et al (2007) Identifi cation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561-566
83. Horn L, Pao W (2009) EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27(26):4232-4235
84. Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247-4253
85. Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and effi cacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275-4283
86. Camidge DR, Bang Y, Kwak EL et al (2011) Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 29(15 suppl):2501
87. Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734-1739
88. Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifi es oncogenic kinases in lung cancer. Cell 131(6):1190-1203
89. Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements defi ne a unique molecular class of lung cancers. J Clin Oncol 30(8):863-870
90. McDermott U, Iafrate AJ, Gray NS et al (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68(9):3389-3395
91. Mascaux C, Iannino N, Martin B et al (2005) The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 92(1):131-139
92. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291-3310
93. Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323(9):561-565
94. Riely GJ, Kris MG, Rosenbaum D et al (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14(18):5731-5734
95. Graziano SL, Gamble GP, Newman NB et al (1999) Prognostic signifi cance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17(2):668-675
96. Mao C, Qiu LX, Liao RY et al (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 69(3):272-278
97. Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962-972
98. Chen Z, Cheng K, Walton Z et al (2012) A murine lung cancer co-clinical trial identifi es genetic modifi ers of therapeutic response. Nature 483(7391):613-617
99. Engelman JA, Chen L, Tan X et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14(12):1351-1356
100. Sos ML, Michel K, Zander T et al (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119(6):1727-1740
101. Corcoran RB, Cheng KA, Hata AN et al (2013) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23(1):121-128
102. Puyol M, Martin A, Dubus P et al (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18(1):63-73
103. Vicent S, Chen R, Sayles LC et al (2010) Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 120(11):3940-3952
104. Meylan E, Dooley AL, Feldser DM et al (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462(7269):104-107
105. Barbie DA, Tamayo P, Boehm JS et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462(7269):108-112
106. Huqun, Ishikawa R, Zhang J et al (2012) Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 118(6):1599-1606
107. Ahmed AU, Schmidt RL, Park CH et al (2008) Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 100(22):1606-1629
108. Kumar MS, Hancock DC, Molina-Arcas M et al (2012) The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149(3):642-655
109. Sunaga N, Imai H, Shimizu K et al (2012) Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 130(8):1733-1744
110. Seo JS, Ju YS, Lee WC et al (2012) The transcriptional landscape and mutational profi le of lung adenocarcinoma. Genome Res 22(11):2109-2119
111. Ma PC, Jagadeeswaran R, Jagadeesh S et al (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65(4):1479-1488
112. Cappuzzo F, Marchetti A, Skokan M et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27(10):1667-1674
113. Peruzzi B, Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12(12):3657-3660
114. Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-925
115. Sulpice E, Ding S, Muscatelli-Groux B et al (2009) Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell (Under the auspices of the European Cell Biology Organization) 101(9):525-539
116. Spigel DR, Ervin TJ, Ramlau R et al. Final effi cacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505)
117. Schiller JH, Akerley WL, Brugger W et al (2010) Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s (suppl; abstr LBA7502)
118. Burke A. Foundation medicine: Personalizing cancer drugs. MIT Technol Rev. http://www.technologyreview.com/. Accessed 21 Feb 2012
119. Heger M. Caris Adds Next-Gen Sequencing to portfolio of molecular tumor profi ling technologies. Clinical sequencing news. http://www.genomeweb.com/. Accessed 06 Feb 2013
120. Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis. Clin Lung Cancer 12(6):393-401
121. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabinebased chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27(34):5808-5815
122. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101-1110
123. Li T, Kung HJ, Mack PC et al (2013) Genotyping and genomic profi ling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol 31(8):1039-1049
124. Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profi ling in human cancer. Nat Genet 39(3):347-351
125. Su Z, Dias-Santagata D, Duke M et al (2011) A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 13(1):74-84
126. Sequist LV, Heist RS, Shaw AT et al (2011) Implementing multiplexed genotyping of nonsmall- cell lung cancers into routine clinical practice. Ann Oncol 22(12):2616-2624
127. Govindan R, Ding L, Griffi th M et al (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150(6):1121-1134
128. Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107-1120
129. Peifer M, Fernandez-Cuesta L, Sos ML et al (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44(10):1104-1110
130. Rudin CM, Durinck S, Stawiski EW et al (2012) Comprehensive genomic analysis identifi es SOX2 as a frequently amplifi ed gene in small-cell lung cancer. Nat Genet 44(10): 1111-1116
131. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-525
132. Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169-1180
133. Oxnard GR, Arcila ME, Chmielecki J et al (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17(17):5530-5537